These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 23346831)

  • 41. Re: "Estimating the relative risk in cohort studies and clinical trials of common outcomes".
    Deddens JA; Petersen MR
    Am J Epidemiol; 2004 Jan; 159(2):213-4; author reply 214-5. PubMed ID: 14718224
    [No Abstract]   [Full Text] [Related]  

  • 42. Controlled trials and risk of harm.
    Edwards IR
    Drug Saf; 2008; 31(11):961-3. PubMed ID: 18840016
    [No Abstract]   [Full Text] [Related]  

  • 43. Hazard ratios in cancer clinical trials--a primer.
    Blagoev KB; Wilkerson J; Fojo T
    Nat Rev Clin Oncol; 2012 Jan; 9(3):178-83. PubMed ID: 22290283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can medical practice be free of risk?
    Clarke C
    J R Soc Med; 1979 Jan; 72(1):35-8. PubMed ID: 399617
    [No Abstract]   [Full Text] [Related]  

  • 45. [Cost-effectiveness analysis of treatment options using the "number-needed-to-treat"].
    Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(7):330-1. PubMed ID: 24268910
    [No Abstract]   [Full Text] [Related]  

  • 46. General versus specific inquiry with SAFTEE.
    Levine J; Schooler NR
    J Clin Psychopharmacol; 1992 Dec; 12(6):448. PubMed ID: 1474186
    [No Abstract]   [Full Text] [Related]  

  • 47. [Reply].
    Gómez-Acebo I; Dierssen-Sotos T; Llorca J
    Med Clin (Barc); 2014 Apr; 142(7):331. PubMed ID: 24268911
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of toxicological science in risk assessment and risk management.
    Goldstein BD
    Adv Exp Med Biol; 2001; 500():651-6. PubMed ID: 11765011
    [No Abstract]   [Full Text] [Related]  

  • 49. Will risk evaluation and mitigation strategies ever be accepted?
    Li EC
    J Natl Compr Canc Netw; 2011 Jul; 9(7):696-9. PubMed ID: 21715721
    [No Abstract]   [Full Text] [Related]  

  • 50. Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019.
    Elliott MH; Skydel JJ; Dhruva SS; Ross JS; Wallach JD
    JAMA Intern Med; 2021 Feb; 181(2):282-284. PubMed ID: 33226398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risks: Absolute or Relative-What should I care about?
    Thromb Res; 2018 May; 165():116. PubMed ID: 29739533
    [No Abstract]   [Full Text] [Related]  

  • 52. Number needed to treat can be helpful: a response to Andrade.
    Citrome L; Ketter TA
    J Clin Psychiatry; 2015 Sep; 76(9):e1136. PubMed ID: 26455680
    [No Abstract]   [Full Text] [Related]  

  • 53. Dr Andrade replies.
    Andrade C
    J Clin Psychiatry; 2015 Sep; 76(9):e1137. PubMed ID: 26455681
    [No Abstract]   [Full Text] [Related]  

  • 54. Death of the placebo.
    Abramson HA
    J Asthma Res; 1966 Dec; 4(2):89-91. PubMed ID: 5959136
    [No Abstract]   [Full Text] [Related]  

  • 55. Statistics commentary series: commentary #4--relative risk and the number needed to treat.
    Streiner DL
    J Clin Psychopharmacol; 2014 Oct; 34(5):549-51. PubMed ID: 25119252
    [No Abstract]   [Full Text] [Related]  

  • 56. Numbers needed to treat and to harm should be included in research.
    Hawkins J
    BMJ; 2017 Mar; 356():j1265. PubMed ID: 28283495
    [No Abstract]   [Full Text] [Related]  

  • 57. Relative risk rather than absolute risk reduction should be preferred to sensitise the public to preventive actions.
    Chapelle N; Martel M; Barkun AN; Bardou M
    Gut; 2022 Jun; 71(6):1045-1046. PubMed ID: 33811040
    [No Abstract]   [Full Text] [Related]  

  • 58. Measures of Association.
    Gogtay NJ
    J Assoc Physicians India; 2016 Dec; 64(12):70-73. PubMed ID: 28405990
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of beta-blockers on mortality in patients with heart failure and atrial fibrillation: A meta-analysis of observational cohort and randomized controlled studies.
    Ma GG; Fang Q; Wang FX
    Cardiol J; 2019; 26(6):744-752. PubMed ID: 30009373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [How I explore ... a risk difference in the occurrence of an event in clinical trials].
    Scheen AJ; Ernest P; Jandrain B
    Rev Med Liege; 2012 Nov; 67(11):597-602. PubMed ID: 23346831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.